Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 19];7(2):s129. Available from: https://skin.dermsquared.com/skin/article/view/1991